Sully.ai vs Biogen
Side-by-side comparison of AI visibility scores, market position, and capabilities
SF healthcare AutonomousOS automating clinical documentation and prior auth for hospitals; YC $30.5M Sequoia Scout/AUM Ventures Series A Jan 2025 competing with Nuance DAX and Abridge for AI-powered physician workflow automation.
About
Sully.ai is a San Francisco-based healthcare AI company — backed by Y Combinator with $30.5 to $32.1 million raised including a $21.83 million Series A in January 2025 from AUM Ventures, Leonis Capital, SemperVirens VC, and Sequoia Scout Fund — providing hospitals, physician practices, and health systems with an AutonomousOS platform that automates clinical documentation (ambient AI scribing that generates SOAP notes from patient-physician conversations), administrative workflows (prior authorization processing, insurance eligibility verification, scheduling automation), and revenue cycle management tasks that consume 30-40% of physician time and hospital administrative labor. Founded in 2023 by Ahmed Nasser and Ahmed Omar, Sully.ai has 49 employees and serves healthcare providers globally with AI agents that autonomously execute multi-step clinical and administrative processes without requiring physician or staff intervention.
Cambridge MA neuroscience biopharma (NASDAQ: BIIB) at $9.7B 2024 revenue; LEQEMBI $87M Q4 (Alzheimer's first-in-class amyloid therapy), SKYCLARYS $102M Q4 (Friedreich's ataxia), MS franchise declining vs. Eli Lilly donanemab.
About
Biogen Inc. is a Cambridge, Massachusetts-based neuroscience biopharmaceutical company — publicly traded on NASDAQ (NASDAQ: BIIB) as an S&P 500 Health Care component — researching, developing, and commercializing therapies for neurological, neurodegenerative, and neurodevelopmental diseases including Alzheimer's disease, multiple sclerosis, spinal muscular atrophy, and rare neurological conditions through approximately 7,400 employees worldwide. In fiscal year 2024, Biogen reported total revenue of $9.7 billion (-2% year-over-year) and GAAP diluted EPS of $11.18 (+40%), reflecting significant cost-cutting that improved profitability despite modest revenue decline. Revenue decline was driven by continued erosion in the core multiple sclerosis franchise (TECFIDERA, AVONEX, TYSABRI facing generic and biosimilar competition) while new product revenue grew: LEQEMBI (lecanemab, Alzheimer's disease, partnered with Eisai) generated approximately $87 million in Q4 2024 global sales — reflecting the slow but building commercial trajectory of the first drug to slow Alzheimer's cognitive decline — and SKYCLARYS (omaveloxolone, Friedreich's ataxia) generated $102 million in Q4, nearly double the year-earlier period. CEO Christopher Viehbacher, who joined in 2022 from Genentech's parent Roche, has led a strategic restructuring that includes cost reduction, pipeline refocus on high-probability neurology programs, and the LEQEMBI commercial execution through a partnership model with Eisai.
AI Visibility Head-to-Head
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.